Hively Brad 4

4 · Oncology Institute, Inc. · Filed Jun 5, 2025

Form 4

Period: 2025-06-03

Director

Transactions

Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-06-03+131,297→ 0 total
Exercise: $1.87Exp: 2032-11-17→ Common Stock (131,297 underlying)
Sale
Common Stock
2025-06-03$2.87/sh−1,867,605$5,360,587→ 712,033 total
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-06-03+105,320→ 0 total
Exercise: $0.48Exp: 2033-03-17→ Common Stock (105,320 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-06-03+946,460→ 0 total
Exercise: $0.85Exp: 2029-12-02→ Common Stock (946,460 underlying)
Exercise/Conversion
Common Stock
2025-06-03$0.85/sh+684,528$581,849→ 1,396,561 total
Exercise/Conversion
Common Stock
2025-06-03$0.48/sh+105,320$50,659→ 1,501,881 total
Exercise/Conversion
Common Stock
2025-06-03$1.87/sh+131,297$245,525→ 1,633,178 total
Exercise/Conversion
Common Stock
2025-06-03$0.85/sh+946,460$804,491→ 2,579,638 total
Sale
Common Stock
2025-06-03$2.87/sh−108,532$311,519→ 603,501 total
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-06-03+684,528→ 0 total
Exercise: $0.85Exp: 2029-12-02→ Common Stock (684,528 underlying)

Footnotes (6)

[F1]Represents sale of Common Stock acquired from previously vested RSU awards.
[F2]These options vested monthly for 36 months following November 12, 2021.
[F3]These options vested monthly starting March 17, 2023, with cancellation of remaining options pursuant to Note 6 below.
[F4]These options vested monthly starting November 17, 2022, with cancellation of remaining options pursuant to Note 6 below.
[F5]These options vested monthly for 48 months following December 2, 2019.
[F6]Pursuant to a Transition Agreement with the Reporting Person, all unvested options were cancelled after June 30, 2024.

Documents

1 file